CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, May 8, 2026
Harbour BioMed announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for HBM7004, allowing the company to initiate a first-in-human Phase 1 clinical trial evaluating the investigational bispecific antibody in patients with advanced solid tumors. The regulatory clearance represents a major development milestone for Harbour BioMed’s oncology pipeline and advances the company’s broader strategy of developing next-generation antibody therapeutics using its proprietary HBICE® bispecific antibody platform. The upcoming Phase 1 study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of HBM7004 in patients with advanced solid malignancies who have limited treatment options.
HBM7004 Advances Harbour BioMed’s Bispecific Antibody Oncology Pipeline
HBM7004 is a novel B7H4xCD3 bispecific antibody engineered to redirect and activate T cells against B7H4-expressing tumor cells. The investigational therapy was developed using Harbour BioMed’s proprietary HBICE® platform, which is designed to create immune cell engager therapies capable of improving anti-cancer activity while potentially reducing systemic toxicity commonly associated with earlier generations of T-cell engaging therapies. B7H4 has emerged as an increasingly important immuno-oncology target because of its high expression across several difficult-to-treat solid tumors, including ovarian, breast, endometrial, and lung cancers, while maintaining relatively limited expression in normal tissues. This selective expression profile has positioned B7H4 as an attractive target for next-generation cancer immunotherapies seeking improved precision and safety.
According to Harbour BioMed, preclinical studies demonstrated that HBM7004 induces B7H4-dependent T-cell activation directly within the tumor microenvironment, potentially improving tumor-selective immune responses while minimizing broader systemic immune activation. In multiple animal models, the therapy showed strong anti-tumor efficacy, favorable in vivo stability, and reduced systemic toxicity. The company also reported that HBM7004 exhibited significant synergistic activity when combined with a B7H4x4-1BB bispecific antibody, particularly under low effector-to-target cell ratio conditions, suggesting the potential for an expanded therapeutic window and combination therapy opportunities in future clinical development.
First-in-Human Phase 1 Trial Targets Advanced Solid Tumors
Advertisement
The newly authorized Phase 1 clinical trial will represent the first human evaluation of HBM7004 and is expected to focus initially on dose escalation and safety assessment in patients with advanced or metastatic solid tumors. The study will evaluate multiple clinical parameters, including safety, tolerability, pharmacokinetics, and early evidence of anti-tumor activity. First-in-human oncology studies are critical for determining optimal dosing strategies and identifying preliminary signals of clinical efficacy that may support expansion into later-stage development programs.
Harbour BioMed stated that the IND clearance further validates the flexibility and “plug-and-play” capabilities of its HBICE® platform, which is designed to generate a range of bispecific antibody candidates targeting different tumor antigens and immune activation pathways. The company continues to focus on expanding its immuno-oncology pipeline through proprietary antibody technologies aimed at addressing significant unmet medical needs across cancer treatment. Founder, Chairman, and Chief Executive Officer Dr. Jingsong Wang described the FDA clearance as an important advancement for the company’s oncology portfolio and emphasized confidence in the potential of HBM7004 to provide clinical benefit for patients with advanced solid tumors.
Bispecific Antibody Therapies Continue Expanding in Oncology
The advancement of HBM7004 reflects broader industry momentum surrounding bispecific antibody therapies, which have become one of the fastest-growing segments within oncology drug development. Unlike conventional monoclonal antibodies that target a single antigen, bispecific antibodies are engineered to simultaneously bind two different targets, enabling more precise immune system activation against cancer cells. CD3-targeting bispecific antibodies in particular have generated substantial clinical interest because of their ability to recruit and activate cytotoxic T cells directly at tumor sites.
At the same time, developers continue working to overcome safety challenges associated with T-cell engager therapies, including cytokine release syndrome and off-target immune activation. Harbour BioMed’s approach seeks to address some of these limitations through tumor-selective activation mechanisms and optimized antibody engineering. As competition intensifies within the bispecific antibody market, early clinical performance from first-in-human studies such as the HBM7004 program may play an important role in shaping future development strategies for next-generation solid tumor immunotherapies.
Source: Harbour BioMed press release
